Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

And even after the significant gains it has experienced in recent years, it might still be early enough to get on the ...

Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

We recently published Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc ...

The global Analytical Standards Market , valued at USD 1.44 billion in 2022 , is projected to expand at a robust CAGR of 5.9% ...

Global companies have been hit with a brutal $320 billion in lost profit since 2017, and it has nothing to do with bad ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...

Trump has rolled back many of his steepest tariffs over recent months, including a sky-high levy on China, the top source of ...